FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2595681737> ?p ?o ?g. }

• W2595681737 endingPage "2892" @default.
• W2595681737 startingPage "2881" @default.
• W2595681737 abstract "BACKGROUND Antithymocyte globulin (ATG) is an important component of conditioning regimens to prevent severe graft-versus-host disease (GVHD) in patients undergoing unmanipulated, haploidentical stem cell transplantation (haplo-SCT). However, to the authors' knowledge, the optimal dose of ATG is unknown. METHODS In this prospective, randomized trial, the authors compared the long-term outcomes of 2 ATG doses (rabbit thymoglobulin) used in myeloablative conditioning before unmanipulated haplo-HSCT. Patients were randomly assigned (1:1) to received 10 mg/kg (ATG-10) or 6 mg/kg (ATG-6) of ATG. Analysis of disease-free survival, GVHD-free/recurrence-free survival (GRFS), disease recurrence, nonrecurrence mortality, and chronic GVHD (cGVHD) included the entire population. Late effects were assessed in disease-free patients who had survived for at least 6 months and had received regular follow-up evaluations. RESULTS A total of 224 patients were recruited. The median follow-up period was 1614 days (range, 28-1929 days). The rate of infection-related deaths in ATG-10 arm was double that of the ATG-6 arm (14.3% vs 7.1%; P = .084). The 5-year cumulative incidence was comparable between the ATG-6 and ATG-10 groups for disease recurrence (12.8% vs 13.4%; P = .832) and nonrecurrence mortality (11.6% vs 17.0%; P = .263). The 5-year probability of disease-free survival was comparable between the groups (75.6% vs 69.6%; P = .283). The 5-year cumulative incidence of cGVHD was found to be higher with ATG-6 (75.0% vs 56.3% [P = .007] and moderate-to-severe cGVHD: 56.3% vs 30.4% [P<.0001]) as well as that for late effects (71.2% vs 56.9%; P = .043). The 5-year probability of GRFS was higher in the ATG-10 group (41.0% vs 26.8%; P = .008). In the multivariate analysis, ATG-10 was found to be associated with a lower risk of cGVHD and improved GRFS. CONCLUSIONS ATG-10 was found to be associated with better GVHD prevention and superior GRFS, but an increase in infection-related deaths. Cancer 2017;123:2881–92. © 2017 American Cancer Society." @default.
• W2595681737 created "2017-03-23" @default.
• W2595681737 creator A5038357890 @default.
• W2595681737 creator A5046424825 @default.
• W2595681737 creator A5047932271 @default.
• W2595681737 creator A5051030924 @default.
• W2595681737 creator A5051211027 @default.
• W2595681737 creator A5055494772 @default.
• W2595681737 creator A5061407928 @default.
• W2595681737 creator A5065894155 @default.
• W2595681737 creator A5067347223 @default.
• W2595681737 creator A5072208411 @default.
• W2595681737 creator A5078632164 @default.
• W2595681737 creator A5079594267 @default.
• W2595681737 creator A5081663648 @default.
• W2595681737 creator A5087610827 @default.
• W2595681737 date "2017-03-16" @default.
• W2595681737 modified "2023-10-16" @default.
• W2595681737 title "Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial" @default.
• W2595681737 cites W1584309797 @default.
• W2595681737 cites W1973617793 @default.
• W2595681737 cites W1982760631 @default.
• W2595681737 cites W2000831487 @default.
• W2595681737 cites W2015758016 @default.
• W2595681737 cites W2017908149 @default.
• W2595681737 cites W2019111335 @default.
• W2595681737 cites W2057094244 @default.
• W2595681737 cites W2057952506 @default.
• W2595681737 cites W2060578002 @default.
• W2595681737 cites W2061595804 @default.
• W2595681737 cites W2089739646 @default.
• W2595681737 cites W2090726866 @default.
• W2595681737 cites W2102866713 @default.
• W2595681737 cites W2121844342 @default.
• W2595681737 cites W2127419842 @default.
• W2595681737 cites W2127975197 @default.
• W2595681737 cites W2128812336 @default.
• W2595681737 cites W2164036788 @default.
• W2595681737 cites W2164885965 @default.
• W2595681737 cites W2168028665 @default.
• W2595681737 cites W2209448786 @default.
• W2595681737 cites W2233354089 @default.
• W2595681737 cites W2282882943 @default.
• W2595681737 cites W2314356636 @default.
• W2595681737 cites W2618073389 @default.
• W2595681737 doi "https://doi.org/10.1002/cncr.30540" @default.
• W2595681737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28301690" @default.
• W2595681737 hasPublicationYear "2017" @default.
• W2595681737 type Work @default.
• W2595681737 sameAs 2595681737 @default.
• W2595681737 citedByCount "53" @default.
• W2595681737 countsByYear W25956817372018 @default.
• W2595681737 countsByYear W25956817372019 @default.
• W2595681737 countsByYear W25956817372020 @default.
• W2595681737 countsByYear W25956817372021 @default.
• W2595681737 countsByYear W25956817372022 @default.
• W2595681737 countsByYear W25956817372023 @default.
• W2595681737 crossrefType "journal-article" @default.
• W2595681737 hasAuthorship W2595681737A5038357890 @default.
• W2595681737 hasAuthorship W2595681737A5046424825 @default.
• W2595681737 hasAuthorship W2595681737A5047932271 @default.
• W2595681737 hasAuthorship W2595681737A5051030924 @default.
• W2595681737 hasAuthorship W2595681737A5051211027 @default.
• W2595681737 hasAuthorship W2595681737A5055494772 @default.
• W2595681737 hasAuthorship W2595681737A5061407928 @default.
• W2595681737 hasAuthorship W2595681737A5065894155 @default.
• W2595681737 hasAuthorship W2595681737A5067347223 @default.
• W2595681737 hasAuthorship W2595681737A5072208411 @default.
• W2595681737 hasAuthorship W2595681737A5078632164 @default.
• W2595681737 hasAuthorship W2595681737A5079594267 @default.
• W2595681737 hasAuthorship W2595681737A5081663648 @default.
• W2595681737 hasAuthorship W2595681737A5087610827 @default.
• W2595681737 hasBestOaLocation W25956817371 @default.
• W2595681737 hasConcept C120665830 @default.
• W2595681737 hasConcept C121332964 @default.
• W2595681737 hasConcept C126322002 @default.
• W2595681737 hasConcept C141071460 @default.
• W2595681737 hasConcept C168563851 @default.
• W2595681737 hasConcept C188816634 @default.
• W2595681737 hasConcept C2777408962 @default.
• W2595681737 hasConcept C2777630719 @default.
• W2595681737 hasConcept C2779972918 @default.
• W2595681737 hasConcept C2780303639 @default.
• W2595681737 hasConcept C2908647359 @default.
• W2595681737 hasConcept C2911091166 @default.
• W2595681737 hasConcept C61511704 @default.
• W2595681737 hasConcept C71924100 @default.
• W2595681737 hasConcept C88879693 @default.
• W2595681737 hasConcept C90924648 @default.
• W2595681737 hasConcept C99454951 @default.
• W2595681737 hasConceptScore W2595681737C120665830 @default.
• W2595681737 hasConceptScore W2595681737C121332964 @default.
• W2595681737 hasConceptScore W2595681737C126322002 @default.
• W2595681737 hasConceptScore W2595681737C141071460 @default.
• W2595681737 hasConceptScore W2595681737C168563851 @default.
• W2595681737 hasConceptScore W2595681737C188816634 @default.
• W2595681737 hasConceptScore W2595681737C2777408962 @default.
• W2595681737 hasConceptScore W2595681737C2777630719 @default.

• next